Optimal management of behavioural disorders associated with dementia

C. Andrew Class, Lon Schneider, Martin Farlow

Research output: Contribution to journalArticle

31 Citations (Scopus)

Abstract

Behavioural disorders occur with great frequency in patients with dementia. They are the major reason for admission of these patients to nursing homes. However, there have been few controlled trials of many of the commonly used drugs to guide therapy. To treat these conditions successfully, an adequate description of target symptoms of the behaviours to be corrected and a thorough investigation to identify precipitating causes are essential. Behavioural problems in dementia patients may result from physical illnesses, adverse drug effects, environmental changes, psychiatric syndromes (i.e. depression, delirium or psychosis) or the dementing illness itself. Therapeutic strategies should address the underlying cause whenever possible. Although pharmacological therapies are commonly employed, their efficacy is often modest and adverse effects can be quite significant. Ongoing reassessments are essential to maximise symptomatic benefits and minimise adverse effects. Several trials with different drugs are often necessary before an effective therapy is found. Anticholinergic adverse effects, which occur commonly with many antipsychotic and antidepressant medications, may worsen the cognitive and memory deficits that form the primary symptoms of dementia in these patients. This article summarises the use of the various psychoactive medications that target common behavioural disturbances, including agitation, psychosis, depression and sleep disturbances, in dementia patients. General guidelines regarding dosage, potential adverse effects and duration of therapy are discussed.

Original languageEnglish
Pages (from-to)95-106
Number of pages12
JournalDrugs and Aging
Volume10
Issue number2
StatePublished - 1997

Fingerprint

Dementia
Psychotic Disorders
Pharmaceutical Preparations
Depression
Therapeutics
Delirium
Patient Admission
Memory Disorders
Cholinergic Antagonists
Nursing Homes
Antidepressive Agents
Antipsychotic Agents
Psychiatry
Sleep
Pharmacology
Guidelines

ASJC Scopus subject areas

  • Pharmacology
  • Geriatrics and Gerontology

Cite this

Optimal management of behavioural disorders associated with dementia. / Class, C. Andrew; Schneider, Lon; Farlow, Martin.

In: Drugs and Aging, Vol. 10, No. 2, 1997, p. 95-106.

Research output: Contribution to journalArticle

Class, C. Andrew ; Schneider, Lon ; Farlow, Martin. / Optimal management of behavioural disorders associated with dementia. In: Drugs and Aging. 1997 ; Vol. 10, No. 2. pp. 95-106.
@article{f62984f75e5a49dca41b1e279843e008,
title = "Optimal management of behavioural disorders associated with dementia",
abstract = "Behavioural disorders occur with great frequency in patients with dementia. They are the major reason for admission of these patients to nursing homes. However, there have been few controlled trials of many of the commonly used drugs to guide therapy. To treat these conditions successfully, an adequate description of target symptoms of the behaviours to be corrected and a thorough investigation to identify precipitating causes are essential. Behavioural problems in dementia patients may result from physical illnesses, adverse drug effects, environmental changes, psychiatric syndromes (i.e. depression, delirium or psychosis) or the dementing illness itself. Therapeutic strategies should address the underlying cause whenever possible. Although pharmacological therapies are commonly employed, their efficacy is often modest and adverse effects can be quite significant. Ongoing reassessments are essential to maximise symptomatic benefits and minimise adverse effects. Several trials with different drugs are often necessary before an effective therapy is found. Anticholinergic adverse effects, which occur commonly with many antipsychotic and antidepressant medications, may worsen the cognitive and memory deficits that form the primary symptoms of dementia in these patients. This article summarises the use of the various psychoactive medications that target common behavioural disturbances, including agitation, psychosis, depression and sleep disturbances, in dementia patients. General guidelines regarding dosage, potential adverse effects and duration of therapy are discussed.",
author = "Class, {C. Andrew} and Lon Schneider and Martin Farlow",
year = "1997",
language = "English",
volume = "10",
pages = "95--106",
journal = "Drugs and Aging",
issn = "1170-229X",
publisher = "Adis International Ltd",
number = "2",

}

TY - JOUR

T1 - Optimal management of behavioural disorders associated with dementia

AU - Class, C. Andrew

AU - Schneider, Lon

AU - Farlow, Martin

PY - 1997

Y1 - 1997

N2 - Behavioural disorders occur with great frequency in patients with dementia. They are the major reason for admission of these patients to nursing homes. However, there have been few controlled trials of many of the commonly used drugs to guide therapy. To treat these conditions successfully, an adequate description of target symptoms of the behaviours to be corrected and a thorough investigation to identify precipitating causes are essential. Behavioural problems in dementia patients may result from physical illnesses, adverse drug effects, environmental changes, psychiatric syndromes (i.e. depression, delirium or psychosis) or the dementing illness itself. Therapeutic strategies should address the underlying cause whenever possible. Although pharmacological therapies are commonly employed, their efficacy is often modest and adverse effects can be quite significant. Ongoing reassessments are essential to maximise symptomatic benefits and minimise adverse effects. Several trials with different drugs are often necessary before an effective therapy is found. Anticholinergic adverse effects, which occur commonly with many antipsychotic and antidepressant medications, may worsen the cognitive and memory deficits that form the primary symptoms of dementia in these patients. This article summarises the use of the various psychoactive medications that target common behavioural disturbances, including agitation, psychosis, depression and sleep disturbances, in dementia patients. General guidelines regarding dosage, potential adverse effects and duration of therapy are discussed.

AB - Behavioural disorders occur with great frequency in patients with dementia. They are the major reason for admission of these patients to nursing homes. However, there have been few controlled trials of many of the commonly used drugs to guide therapy. To treat these conditions successfully, an adequate description of target symptoms of the behaviours to be corrected and a thorough investigation to identify precipitating causes are essential. Behavioural problems in dementia patients may result from physical illnesses, adverse drug effects, environmental changes, psychiatric syndromes (i.e. depression, delirium or psychosis) or the dementing illness itself. Therapeutic strategies should address the underlying cause whenever possible. Although pharmacological therapies are commonly employed, their efficacy is often modest and adverse effects can be quite significant. Ongoing reassessments are essential to maximise symptomatic benefits and minimise adverse effects. Several trials with different drugs are often necessary before an effective therapy is found. Anticholinergic adverse effects, which occur commonly with many antipsychotic and antidepressant medications, may worsen the cognitive and memory deficits that form the primary symptoms of dementia in these patients. This article summarises the use of the various psychoactive medications that target common behavioural disturbances, including agitation, psychosis, depression and sleep disturbances, in dementia patients. General guidelines regarding dosage, potential adverse effects and duration of therapy are discussed.

UR - http://www.scopus.com/inward/record.url?scp=0031040888&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0031040888&partnerID=8YFLogxK

M3 - Article

VL - 10

SP - 95

EP - 106

JO - Drugs and Aging

JF - Drugs and Aging

SN - 1170-229X

IS - 2

ER -